硕世生物
(688399)
| 流通市值：34.30亿 | | | 总市值：34.30亿 |
| 流通股本：1.24亿 | | | 总股本：1.24亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 147,426,847.79 | 78,583,971.79 | 339,047,470.66 | 257,507,844.76 |
| 营业收入 | 147,426,847.79 | 78,583,971.79 | 339,047,470.66 | 257,507,844.76 |
| 二、营业总成本 | 178,153,329.2 | 90,699,617.91 | 424,137,643.57 | 306,781,790.65 |
| 营业成本 | 53,882,100.53 | 32,441,775.11 | 124,917,275.05 | 94,729,081.39 |
| 税金及附加 | 3,491,476.62 | 1,766,982.49 | 7,187,598.26 | 5,395,900.14 |
| 销售费用 | 53,248,746.6 | 24,940,869 | 128,569,216.18 | 94,147,522.55 |
| 管理费用 | 31,132,573.27 | 14,284,406.03 | 82,465,108.72 | 49,138,901.71 |
| 研发费用 | 32,351,608.29 | 14,864,410.61 | 78,724,145.78 | 61,550,504.79 |
| 财务费用 | 4,046,823.89 | 2,401,174.67 | 2,274,299.58 | 1,819,880.07 |
| 其中:利息费用 | 4,503,836.97 | 1,967,193.86 | 8,532,163.08 | 6,318,679.76 |
| 其中:利息收入 | 1,710,364.54 | 76,572.89 | 7,042,466.36 | 4,986,114.85 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 25,063,192.33 | 13,807,608.99 | 47,555,955.77 | 31,779,316.48 |
| 加:投资收益 | 4,203,633.14 | 1,870,144.19 | 6,979,477.81 | 5,460,640.69 |
| 资产处置收益 | 535,015.75 | 596,415.89 | 102,432.88 | 183,362.84 |
| 资产减值损失(新) | -2,938,914.83 | -500,058.28 | -39,459,781.8 | -11,808,595.38 |
| 信用减值损失(新) | 21,507,707.85 | 17,759,918.59 | 16,096,392.87 | 12,353,476.01 |
| 其他收益 | 7,221,612.25 | 3,806,570.91 | 23,849,070.81 | 18,260,142.66 |
| 四、营业利润 | 24,865,765.08 | 25,224,954.17 | -29,966,624.57 | 6,954,397.41 |
| 加:营业外收入 | 1,980,397.35 | 1,464,516.95 | 1,872,828.95 | 242,549.54 |
| 减:营业外支出 | 134,264.54 | 26,508.79 | 3,963,969.88 | 71,478.22 |
| 五、利润总额 | 26,711,897.89 | 26,662,962.33 | -32,057,765.5 | 7,125,468.73 |
| 减:所得税费用 | 7,147,338.91 | 5,540,718.14 | 9,020,689.05 | 3,973,806.59 |
| 六、净利润 | 19,564,558.98 | 21,122,244.19 | -41,078,454.55 | 3,151,662.14 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 19,564,558.98 | 21,122,244.19 | -41,078,454.55 | 3,151,662.14 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 19,564,558.98 | 21,122,244.19 | -41,078,454.55 | 3,151,662.14 |
| 扣除非经常损益后的净利润 | -19,167,775.78 | -4,012,244.63 | -102,548,192.43 | -41,392,502.88 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.16 | 0.25 | -0.49 | 0.04 |
| (二)稀释每股收益 | 0.16 | 0.25 | -0.49 | 0.04 |
| 八、其他综合收益 | -4,537,383.27 | -2,308,772.26 | 4,220,759.69 | -1,054,497.65 |
| 归属于母公司股东的其他综合收益 | -4,537,383.27 | -2,308,772.26 | 4,220,759.69 | -1,054,497.65 |
| 九、综合收益总额 | 15,027,175.71 | 18,813,471.93 | -36,857,694.86 | 2,097,164.49 |
| 归属于母公司股东的综合收益总额 | 15,027,175.71 | 18,813,471.93 | -36,857,694.86 | 2,097,164.49 |
| 公告日期 | 2026-08-28 | 2026-04-30 | 2026-04-23 | 2025-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |